-+ 0.00%
-+ 0.00%
-+ 0.00%

Edding Genor Wins China Approval for GB268 Cancer Trials

PUBT·11/16/2026 08:32:23
Listen to the news
Edding Genor Wins China Approval for GB268 Cancer Trials
  • Edding Genor received NMPA clearance on Nov. 12, 2026, for two GB268 cancer trials.
  • The Phase Ib/II trial covers monotherapy or combination therapy for metastatic non-small cell lung cancer.
  • The Phase II/III trial evaluates GB268 with chemotherapy as first-line treatment for locally advanced or metastatic biliary tract cancer unsuitable for curative surgery.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261116-12413790), on November 16, 2026, and is solely responsible for the information contained therein.